Peptide and peptide mimetic inhibitors of antigen presentation by HLA-DR class II MHC molecules. Design, structure-activity relationships, and X-ray crystal structures

Journal of Medicinal Chemistry

Volumn 43, Issue 11, 2000, Pages 2135-2148

  Bolin, David R ^a,c   Swain, Amy L ^c   Sarabu, Ramakanth ^c   Berthel, Steven J ^c   Gillespie, Paul ^c   Huby, Nicholas J S ^c   Makofske, Raymond ^c   Orzechowski, Lucja ^c   Perrotta, Agostino ^c   Toth, Katherine ^c   Cooper, Joel P ^c   Jiang, Nan ^c   Falcioni, Fiorenza ^c   Campbell, Robert ^c   Cox, Donald ^c   Gaizband, Diana ^c   Belunis, Charles J ^c   Vidovic, Damir ^c   Ito, Kouichi ^c   Crowther, Robert ^c   Kammlott, Ursula ^c   Zhang, Xiaolei ^c   Palermo, Robert ^c   Weber, David ^c   Guenot, Jeanmarie ^c   Nagy, Zoltan ^c   Olson, Gary L ^b,c   more..

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b Provid Research   (United States)

^c HOFFMANN LA ROCHE INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HLA DR2 ANTIGEN; IMMUNOSUPPRESSIVE AGENT; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2;

ANIMAL CELL; ANTIGEN PRESENTATION; ARTICLE; AUTOIMMUNE DISEASE; DRUG DESIGN; HLA SYSTEM; LIGAND BINDING; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; RHEUMATOID ARTHRITIS; STRUCTURE ACTIVITY RELATION;

ANTIGEN PRESENTATION; BINDING, COMPETITIVE; CARBOHYDRATES; CATHEPSIN B; CELL DIVISION; CRYSTALLOGRAPHY, X-RAY; DIPEPTIDES; HLA-DR ANTIGENS; HUMANS; METHYLATION; MODELS, MOLECULAR; MOLECULAR MIMICRY; PEPTIDE BIOSYNTHESIS; PROTEIN CONFORMATION; STRUCTURE-ACTIVITY RELATIONSHIP; T-LYMPHOCYTES;

EID: 0034214403     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm000034h     Document Type: Article

References (55)

1. Todd, J. A.; Acha-Orbea, H.; Bell, J. I.; Chao, N.; Fronek, Z.; Jacob, C. O.; McDermott, M.; Sinha, A. A.; Timmerman, L.; Steinman, L.; McDevitt, H. O. A molecular basis for MHC class II-associated autoimmunity. Science 1998, 240, 1003-1009.
2. Tiwari, J.; Terasaki, P. HLA and disease association; Springer-Verlag: New York, 1985.
3. Adorini, L.; Muller, S.; Cardinaux, F.; Lehmann, P. V.; Falcioni, F.; Nagy, Z. A. In vivo competition between self-peptides and foreign antigens in T-cell activation. Nature 1988, 334, 623-625.
4. Stern, L. J., Brown, J. H.; Jardetzky, T. S.; Gorga, J. C.; Urban, R. G.; Strominger, J. L.; Wiley, D. C. Crystal structure of the human class II MHC protein HLA-DR1 complexed with an influenza virus peptide. Nature 1994, 368, 215-21. See also Jardetzky, T. S.; Brown, J. H.; Stern, L. J.; Urban, R. G.; Chi, Y.-I.; Stauffacher, C.; Strominger, J. L.; Wiley, D. C. Three-dimensional structure of a human class II histocompatibility molecule complexed with superantigen. Nature 1994, 368, 711-718. Ghosh, P.; Amaya, M.; Mellins, E.; Wiley, D. C. The structure of an intermediate in class II MHC maturation: CLIP bound to HLA-DR3. Nature 1995, 378, 457-462. Brown, J. H.; Jardetzky, T. S.; Gorga, J. C.; Stern, L. J.; Urban. R. G.; Strominger, J. L.; Wiley, D. C. Three-dimensional structure of the human class II histocompatibility antigen HLA-DR1. Nature 1993, 364, 33-39. Dessen, A.; Lawrence, C. M.; Cupo, S.; Zaller, D. M.; Wiley, D. C. X-ray crystal structure of HLA-DR4 (DRA0101, DRB10401) complexed with a peptide from human collagen II. Immunity 1997, 7, 473-481.
5. Stern, L. J., Brown, J. H.; Jardetzky, T. S.; Gorga, J. C.; Urban, R. G.; Strominger, J. L.; Wiley, D. C. Crystal structure of the human class II MHC protein HLA-DR1 complexed with an influenza virus peptide. Nature 1994, 368, 215-21. See also Jardetzky, T. S.; Brown, J. H.; Stern, L. J.; Urban, R. G.; Chi, Y.-I.; Stauffacher, C.; Strominger, J. L.; Wiley, D. C. Three-dimensional structure of a human class II histocompatibility molecule complexed with superantigen. Nature 1994, 368, 711-718. Ghosh, P.; Amaya, M.; Mellins, E.; Wiley, D. C. The structure of an intermediate in class II MHC maturation: CLIP bound to HLA-DR3. Nature 1995, 378, 457-462. Brown, J. H.; Jardetzky, T. S.; Gorga, J. C.; Stern, L. J.; Urban. R. G.; Strominger, J. L.; Wiley, D. C. Three-dimensional structure of the human class II histocompatibility antigen HLA-DR1. Nature 1993, 364, 33-39. Dessen, A.; Lawrence, C. M.; Cupo, S.; Zaller, D. M.; Wiley, D. C. X-ray crystal structure of HLA-DR4 (DRA0101, DRB10401) complexed with a peptide from human collagen II. Immunity 1997, 7, 473-481.
6. Stern, L. J., Brown, J. H.; Jardetzky, T. S.; Gorga, J. C.; Urban, R. G.; Strominger, J. L.; Wiley, D. C. Crystal structure of the human class II MHC protein HLA-DR1 complexed with an influenza virus peptide. Nature 1994, 368, 215-21. See also Jardetzky, T. S.; Brown, J. H.; Stern, L. J.; Urban, R. G.; Chi, Y.-I.; Stauffacher, C.; Strominger, J. L.; Wiley, D. C. Three-dimensional structure of a human class II histocompatibility molecule complexed with superantigen. Nature 1994, 368, 711-718. Ghosh, P.; Amaya, M.; Mellins, E.; Wiley, D. C. The structure of an intermediate in class II MHC maturation: CLIP bound to HLA-DR3. Nature 1995, 378, 457-462. Brown, J. H.; Jardetzky, T. S.; Gorga, J. C.; Stern, L. J.; Urban. R. G.; Strominger, J. L.; Wiley, D. C. Three-dimensional structure of the human class II histocompatibility antigen HLA-DR1. Nature 1993, 364, 33-39. Dessen, A.; Lawrence, C. M.; Cupo, S.; Zaller, D. M.; Wiley, D. C. X-ray crystal structure of HLA-DR4 (DRA0101, DRB10401) complexed with a peptide from human collagen II. Immunity 1997, 7, 473-481.
7. Stern, L. J., Brown, J. H.; Jardetzky, T. S.; Gorga, J. C.; Urban, R. G.; Strominger, J. L.; Wiley, D. C. Crystal structure of the human class II MHC protein HLA-DR1 complexed with an influenza virus peptide. Nature 1994, 368, 215-21. See also Jardetzky, T. S.; Brown, J. H.; Stern, L. J.; Urban, R. G.; Chi, Y.-I.; Stauffacher, C.; Strominger, J. L.; Wiley, D. C. Three-dimensional structure of a human class II histocompatibility molecule complexed with superantigen. Nature 1994, 368, 711-718. Ghosh, P.; Amaya, M.; Mellins, E.; Wiley, D. C. The structure of an intermediate in class II MHC maturation: CLIP bound to HLA-DR3. Nature 1995, 378, 457-462. Brown, J. H.; Jardetzky, T. S.; Gorga, J. C.; Stern, L. J.; Urban. R. G.; Strominger, J. L.; Wiley, D. C. Three-dimensional structure of the human class II histocompatibility antigen HLA-DR1. Nature 1993, 364, 33-39. Dessen, A.; Lawrence, C. M.; Cupo, S.; Zaller, D. M.; Wiley, D. C. X-ray crystal structure of HLA-DR4 (DRA0101, DRB10401) complexed with a peptide from human collagen II. Immunity 1997, 7, 473-481.
8. Stern, L. J., Brown, J. H.; Jardetzky, T. S.; Gorga, J. C.; Urban, R. G.; Strominger, J. L.; Wiley, D. C. Crystal structure of the human class II MHC protein HLA-DR1 complexed with an influenza virus peptide. Nature 1994, 368, 215-21. See also Jardetzky, T. S.; Brown, J. H.; Stern, L. J.; Urban, R. G.; Chi, Y.-I.; Stauffacher, C.; Strominger, J. L.; Wiley, D. C. Three-dimensional structure of a human class II histocompatibility molecule complexed with superantigen. Nature 1994, 368, 711-718. Ghosh, P.; Amaya, M.; Mellins, E.; Wiley, D. C. The structure of an intermediate in class II MHC maturation: CLIP bound to HLA-DR3. Nature 1995, 378, 457-462. Brown, J. H.; Jardetzky, T. S.; Gorga, J. C.; Stern, L. J.; Urban. R. G.; Strominger, J. L.; Wiley, D. C. Three-dimensional structure of the human class II histocompatibility antigen HLA-DR1. Nature 1993, 364, 33-39. Dessen, A.; Lawrence, C. M.; Cupo, S.; Zaller, D. M.; Wiley, D. C. X-ray crystal structure of HLA-DR4 (DRA0101, DRB10401) complexed with a peptide from human collagen II. Immunity 1997, 7, 473-481.
9. (a) Garboczi, D. N.; Ghosh, P.; Utz, F.; Qing, R.; Biddison, W. E.; Wiley, D. C. Structure of the complex between human T-cell receptor, viral peptide and HLA-A2. Nature (London) 1996, 384, 134-141.
10. (b) Garcia, K. C.; Degano, M.; Stanfield, R. L.; Brunmark, A.; Jackson, M. R.; Peterson, P. A.; Teyton, L.; Wilson, I. A. An αβ T cell receptor structure at 2.5 A and its orientation in the TCR-MHC complex. Science 1996, 274, 209-219.
11. (c) Reinherz, E. L.; Tan, K.; Tang, L.; Kern, P.; Liu, J.; Xiong, Y.; Hussey, R. E.; Smolyar, A.; Hare, B.; Zhang, R.; Joachimiak, A.; Chang, H.; Wagner, G.; Wang, J. The crystal structure of a T-cell receptor in complex with peptide and MHC class II. Science 1999, 286, 1913-1921.
12. (a) Hammer, J.; Takacs, B.; Sinigaglia, F. Identification of a motif for HLA-DR1 binding peptides using M13 display libraries. J. Exp. Med. 1993, 176, 1007-1013.
13. (b) Hammer, J.; Valsasnini, P.; Tolba, K.; Bolin, D.; Higelin, J.; Takacs, B.; Sinigaglia, F. Promicsuous and allele-specific anchors in HLA-DR-binding peptides. Cell 1994, 74, 197-203.
14. (c) Hammer, J.; Bono, E.; Gallazzi, F.; Belunis, C.; Nagy, Z. A.; Sinigaglia, F. Precise prediction of major histocompatibility complex class II-peptide interaction based on peptide side chain scanning. J. Exp. Med. 1995, 180, 2353-2358.
15. (d) Hammer, J.; Gallazzi, F.; Bono, E.; Karr, R. W.; Guenot, J.; Valsasini, P.; Nagy, Z. A.; Sinigaglia, F. Peptide binding specificity of HLA-DR4 molecules: Correlation with rheumatoid arthritis association. J. Exp. Med. 1995, 181, 1847-1855.
16. Lamont, A. G.; Powell, M. F.; Colon, S. M.; Miles, C.; Grey, H. M.; Sette, A. The use of peptide analogues with improved stability and MHC binding capacity to inhibit antigen presentation in vitro and in vivo. J. Immunol. 1990, 144 (7), 2493-2498; See also ref 13.
17. Ishioka, G. Y.; Adorini, L.; Guery, J. C.; Gaeta, F. C. A.; LaFond. R.; Alexander, J.; Powell, M. F.; Sette, A.; Grey, H. M. Failure to demonstrate long-lived MHC saturation both in vitro and in vivo. Implications for therapeutic potential of MHC-blocking peptides. J. Immunol. 1994, 152 (9), 4310-4319.
18. Siklodi, B.; Vogt, A. B.; Kropshofer, H,; Falcioni, F.; Molina, M.; Bolin, D. R.; Campbell, R.; Hammerling, G. J.; Nagy, Z. A. Binding affinity independent contribution of peptide length to the stability of peptide-HLA-DR complexes in live antigen presenting cells. Hum. Immunol. 1998, 59 (8), 463-471.
19. (a) Jones, A. B.; Acton, J. J.; Adams, A. D.; Yuen, W.; Nichols, E. A.; Schwartz, C. D.; Wicker, L. S.; Hermes, J. D. Tetrapeptide derived inhibitors of complexation of a class II MHC: fully unnatural ligands. Bioorg. Med. Chem. Lett. 1999, 9, 2115-2118.
20. (b) Jones, A. B.; Acton, J. J.; Rivetna, M. N.; Cummings, R. T.; Cubbon, R. M.; Nichols, E. A.; Schwartz, C. D.; Wicker, L. S.; Hermes, J. D. Tetrapeptide derived inhibitors of complexation of a class II MHC: The peptide backbone is not inviolate. Bioorg. Med. Chem. Lett. 1999, 9, 2109-2114.
21. Falcioni, F.; Ito, K.; Vidovic, D.; Belunis, C.; Campbell, R.; Berthel, S. J.; Bolin, D. R.; Gillespie, P. B.; Nuby, N.; Olson, G. L.; Sarabu, R.; Guenot, J.; Madison, V.; Hammer, J.; Sinigaglia, F.; Steinmetz, M.; Nagy, Z. A. Peptidomimetic compounds that inhibit antigen presentation by autoimmune disease-associated class II major histocompatibility molecules. Nature Biotechnol. 1999, 17, 562-567.
22. (a) Hammer, J.; Valsasnini, P.; Tolba, K.; Bolin, D.; Higelin, J.; Takacs, B.; Sinigaglia, F. Promiscuous and allele-specific anchors in HLA-DR-binding peptides. Cell 1993, 74, 197-203.
23. (b) Hammer, J.; Takacs, B.; Sinigaglia, F. Identification of a motif for HLA-DR1 binding peptides using M13 display libraries. J. Exp. Med. 1992, 176, 1007-1013.
24. Hammer, J.; Belunis, C.; Bolin, D.; Papadopoulos, J.; Walsky, R.; Higelin, J.; Danho, W.; Sinigaglia, F.; Nagy, Z. A. High-affinity binding of short peptides to major histocompatibility complex class II molecules by anchor combinations. Proc. Natl. Acad. Sci. U.S.A. 1994, 91, 4456-4460.
25. Smith, A. B., III; Benowitz, A. B.; Guzman, M. C.; Sprengeler, P. A.; Hirschmann, R.; Schweiger, E. J.; Bolin, D. R.; Nagy, Z.; Campbell, R. M.; Cox, D. C.; Olson, G. L. Design, synthesis and evaluation of a pyrrolinone-peptide hybrid ligand for the class II MHC protein HLA-DR1. J. Am. Chem. Soc. 1998, 120, 12704-12705.
26. Smith, A. B., III; Benowitz, A. B.; Guzman, M. C.; Sprengeler, P. A.; Hirschmann, R.; Schweiger, E. J.; Bolin, D. R.; Nagy, Z.; Campbell, R. M.; Cox, D. C.; Olson, G. L. Design, synthesis and evaluation of a pyrrolinone-peptide hybrid ligand for the class II MHC protein HLA-DR1. J. Am. Chem. Soc. 1998, 120, 12704-12705.
27. (a) Cunningham, B. R.; Rivetna, M.; Tolman, R. L.; Flattery, S. J.; Nichols, E. A.; Schwartz, C. D.; Wicker, L. S.; Hermes, J. D.; Jones, A. B. SAR for MHC class II binding tetrapeptides: Correlation with potential binding site. Bioorg. Med. Chem. Lett. 1997, 7 (1), 19-24.
28. (b) Acton, J. J., III; Adams, A. D.; Hermes, J. D.; Jones, A. B.; Parons, W. H.; Sinclair, P. J. Preparation of peptide lactams as inhibitors of peptide binding to MHC class II proteins. PCT Int. Appl., WO 9716425 A1 970509.
29. Hanson, G. J.; Vuletich, J. L.; Bedell, L. J.; Bono, C. P.; Howard, S. C.; Welply, J. K.; Woulfe, S. L.; Zacheis, M. L. Design of MHC class II ligands using conformationally restricted imino acids at p3 and p5. Bioorg. Med. Chem. Lett. 1996, 6, 1931-36.
30. Jones, A. B.; Acton, J. J., III; Rivetna, M. N.; Cummings, R. T.; Cubbon, R. M.; Nichols, E. A.; Schwartz, C. D.; Wicker, L. S.; Hermes, J. D. Tetrapeptide derived inhibitors of complexation of a class II MHC: The peptide backbone is not inviolate. Bioorg. Med. Chem. Lett. 1999, 9, 2109-14.
31. Jones, A. B.; Acton, J. J., III; Adams, A. D.; Yuen, W.; Nichols, E. A.; Schwartz, C. D.; Wicker, L. S.; Hermes, J. D. Tetrapeptide derived inhibitors of complexation of a class II MHC: Fully unnatural ligands. Bioorg. Med. Chem. Lett. 1999, 9, 2115-18.
32. (a) Hirschmann, R.; Nicolaou, K. C.; Pietranico, S.; Salvino, J.; Leahy, E. M.; Sprengeler, P. A.; Furst, G.; Strader, C. D.; Smith, A. B., III; et al. Nonpeptidal peptidomimetics with β-D-glucose scaffolding. A partial somatostatin agonist bearing a close structural relationship to a potent, selective substance P antagonist. J. Am. Chem. Soc. 1992, 114, 9217-18.
33. (b) Hirschmann, R.; Nicolaou, K. C.; Pietranico, S.; Leahy, E. M.; Salvino, J.; Arison B.; Cichy, M. A.; Spoors, P. G.; Shakespeare, W. C.; et al. De novo design and synthesis of somatostatin non-peptide peptidomimetics utilizing β-D-glucose as a novel scaffolding. J. Am. Chem. Soc. 1993, 115, 12550-68.
34. Manavalan, P.; Momany, F. A. Conformational energy studies on W-methylated analogues of thyrotropin releasing hormone, enkephalin, and luteinizing hormone-releasing hormone. Biopolymers 1980, 19, 1943-73.
35. Miller, S. C.; Scanlon, T. S. Site-selective N-methylation of peptides on solid support. J. Am. Chem. Soc. 1997, 119, 2301-3.
36. Bennett, K.; Levine, T.; Ellis, J. S.; Peanasky, R. J.; Samloff, I. M.; Kay, J.; Chain, B. M. Antigen processing for presentation by class II major histocompatibility complex requires cleavage by cathepsin E. Eur. J. Immunol. 1992, 22 (6), 1519-24.
37. Matsunaga, Y.; Saibara, T.; Kido, H.; Katunuma, N. Participation of cathepsin B in processing of antigen presentation to MHC class II. FEBS Lett. 1993, 324 (3), 325-30.
38. Bushell, G.; Nelson, C.; Chiu, H.; Grimley, C.; Henzel, W.; Burnier, J.; Fong, S.; Evidence supporting a role for cathepsin B in the generation of T cell antigenic epitopes of human growth hormone. Mol. Immunol. 1993, 30 (6), 587-91.
39. (a) Gillespie, P. Cicariello, J.; Olson, G. L. Conformational analysis of dipeptide mimetics, Biopolm./Pept. Sci. 1997, 43, 191-217.
40. (b) Souers, A. J.; Virgilio, A. A.; Rosenquist, S. A.; Fenuik, W.; Ellman, J. A. Identification of a Potent Heterocyclic Ligand To Somatostatin Receptor Subtype 5 by the Synthesis and Screening of β-Turn Mimetic Libraries. J. Am. Chem. Soc. 1999, 121 (9), 1817-1825.
41. Sarabu, R.; et al., manuscript in preparation.
42. Attwood, M. R.; Hassall, C. H.; Krohn, A.; Lawton, G.; Redshaw, S. The design and synthesis of the angiotensin-converting enzyme inhibitor cilazapril and related bicyclic compounds. J. Chem. Soc., Perkin Trans, 1 1986, 1011-19.
43. New, J. S.; Yevich, J. P. Synthesis of the 5H-pyrrolo[2,1-a]-isoindole ring with 1,3-dipolar cycloaddition reactions. J. Heterocycl. Chem. 1984, 21 (5), 1355-60.
44. (a) Herdeis, C.; Hubmann, H. P.; Lotter, H. Synthesis of homochiral 3-substituted glutamic acids and prolines from pyroglutamic acid. Tetrahedron: Asymmetry 1994, 5 (3), 351-4.
45. (b) Chung, J. Y. L.; Wasicak, J. T.; Arnold, W. A.; May, C. S.; Nadzan, A. M.; Holladay, M. W. Conformationally constrained amino acids. Synthesis and optical resolution of 3-substituted proline derivatives. J. Org. Chem. 1990, 55 (1), 270-5.
46. Barany, G.; Merrifield, R. B. Solid-phase peptide synthesis. In The Peptides; Gross, E., Meienhofer, J., Eds.; Academic Press: New York, 1980; Vol. 2, pp 1-284.
47. Rink, H. Solid-phase synthesis of protected peptide fragments using a trialkoxy-diphenyl-methyl ester resin. Tetrahedron Lett. 1987, 28, 3787.
48. Wang, S. S. p-Alkoxybenzyl resin and p-alkoxybenzylcarbonylhydrazide resin for solid-phase synthesis of protected peptide fragments. J. Am. Chem. Soc. 1973, 95, 1328-33.
49. Falcioni, F.; Shah, H.; Vidovic, D.; Morimoto, C.; Belunis, C.; Bolin, D. R.; Nagy, Z. A. Influence of CD26 and integrins on the antigen sensitivity of human memory T cells. Hum. Immunol. 1996, 50, 79-90.
50. Otwinowski, A.; Minor, W. Processing of X-ray diffraction data collected in oscillation mode, In Methods in Enzymology, 276A; Carter, C. W., Jr., Sweet, R. M., Eds.; Academic Press: New York, 1997; pp 307-326.
51. Navaza, J. AmoRe: An automated package for molecular replacement. Acta Crystallogr. D 1994, 50, 157-163.
52. Jardetzky, T. S.; Brown, J. H.; Stern, L. J.; Urban, R. G.; Chi, Y.-I.; Stauffacher, C.; Strominger, J. L.; Wiley, D. C. Three-dimensional structure of a human class II major histocompatibility molecule complexed with superantigen. Nature 1994, 369, 711-718.
53. Swaminathan, S.; Furey, W.; Pletcher, J.; Sax, M. Residues defining V beta specificity in staphylococcal enterotoxins. Nat. Struct. Biol. 1995, 2, 680-686.
54. Brunger, A. T. X-PLOR version 3.1: A system for X-ray crystallography and NMR; Yale University Press: New Haven, CT, 1992.
55. Brunger, A. T.; Adams, P. D.; Clore, G. M.; Delano, W. L.; Gros, P.; Grosse-Kunstleve, R. W.; Jiang, J.-S.; Kuszewski, J.; Nilges, N.; Pannu, N. S.; Read, R. J.; Rice, L. M.; Simonson, T.; Warren, G. L. Crystallography and NMR system (CNS): A new software system for macromolecular structure determination. Acta Crystallogr. 1998, 905-921.